Table 3.

Graft-versus-host disease following non-myeloablative stem cell transplantation.

Classification of GVHD	ATG group (n=24)	FLU group (n=32)	P value
aGVHD within 100 days (n,%)	4 (16.7)	16 (50.0)*	0.018
Grade 1–2	4 (16.7)	10 (31.25)
Grade 3–4	0 (0.0)	6 (18.75)
GVHD post 100 d (n, %)
aGVHD	8 (33.3)	10 (31.2)	0.969
cGVHD	12 (50)	8 (25)	0.274
Mild	4	3
Moderate	4	3
Severe	4	2
Classic cGVHD	6 (25.0)	4 (12.5)	0.298
Overlap GVHD	6 (25.0)	4 (12.5)	0.298
Extensive cGVHD (n,%)	9 (37.5)	3 (9.4)*	0.019
Oral GVHD complications post 100 d (n,%)	3 (12.5)	14 (43.8)*	0.018
Sever infection#	12 (50.0)	8 (25.0)*	0.024
Liver dysfunction	10 (41.7)	22 (68.8)	0.058
Elevated bilirubin	12 (50.0)	6 (18.8)*	0.021
PTLD	2 (8.3)	1 (3.1)	0.565

GVHD – graft-versus-host disease; cGVHD – chronic GVHD; aGVGD – acute GVHD; PTLD – post transplant lymphoproliferative disease. Note: In comparison to ATG group,

^*P<0.05.

^#Sever infection including pulmonary aspergillosis, interstitial pneumonia, cytomegalovirus infection or sepsis.